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Abstract
Background: Following failure of standard systemic chemotherapy, the role of hepatic transarterial therapy for
colorectal hepatic metastasis continues to evolve as the experience with this technique matures. The aim of this
study to gain a better understanding of the value of drug eluting bead therapy when administered to patients with
unresectable colorectal hepatic metastasis.
Methods: This was an open-label, multi-center, single arm study, of unresectable colorectal hepatic metastasis
patients who had failed standard therapy from 10/2006-10/2008. Patients received repeat embolizations with
Irinotecan loaded beads(max 100 mg per embolization) per treating physician's discretion.
Results: Fifty-five patients underwent 99 treatments using Irinotecan drug eluting beads. The median number of
total treatments per patient was 2(range of 1-5). Median length of hospital stay was 23 hours(range 23 hours - 10
days). There were 30(30%) sessions associated with adverse reactions during or after the treatment. The median
disease free and overall survival from the time of first treatment was 247 days and 343 days. Six patients(10%)
were downstaged from their original disease status. Of these, four were treated with surgery and two with RFA.
Neither number of liver lesions, size of liver lesions or extent of liver replacement(<= 25% vs >25%) were
predictors of overall survival. Only the presence of extrahepatic disease(p = 0,001), extent of prior chemotherapy
(failed 1st and 2nd line vs > 2 line failure)(p = 0,007) were predictors of overall survival in multivariate analysis.
Conclusion: Chemoembolization using Irinotecan loaded beads was safe and effective in the treatment of
patients as demonstrated by a minimal complication rate and acceptable tumor response.
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Background
Surgical resection of the affected portion of the liver offers
the best chance for disease-free and overall survival in
patients with colorectal hepatic metastasis (CRHM)[1,2].
Unfortunately, most patients present with disease that is
not amenable to resection or have other contraindications
to surgery. As a result of these limitations, it is estimated
that only 15-30% of patients are suitable surgical candi-
dates at initial presentation.
Following standard systemic chemotherapy, additional
therapies include transarterial chemotherapy, ethanol
injection, cryotherapy, radiofrequency ablation, and
microwave ablation. The role of hepatic transarterial ther-
apy for CRHM continues to evolve as experience with this
technique matures[3]. There have been recent reports of
precision transarterial therapy in metastatic colorectal
cancer with acceptable results[4,5]. Chemoembolization
offers the promise of even more effective control by com-
bining tumor embolization with prolonged and locally
enhanced chemotherapy[6,7]. CRHM are well suited for
chemoembolization through the arterial route, since they
have a predominantly arterial blood supply[8,9], and
most are hypervascularized[10]. Chemoembolization of
liver malignancies, including CRHM, have been reported
since 1981[11].
A new drug eluting bead treatment represents a new but
clinically unproven delivery device that can deposit a
chemotherapeutic agent in the liver with minimal release
into adjacent tissues[12]. The agent is embedded in beads
enough to minimize diffusion by embolizing the terminal
capillaries[13]. Modern angiographic techniques can
deliver these beads directly to the tumor without impos-
ing an undue risk[5]. The objective of treatment with drug
eluting beads is to selectively administer a potentially
lethal dose of chemotherapeutic material to the liver
metastises while minimizing systemic side effects.
Recent reports from Alberti et al, and Fiorentini et al, have
shown that this drug eluting therapy is generally well-tol-
erated by patients[4,5]. Major risks include liver failure
and gastric irritation caused by seepage into the gastroin-
testinal tract. Until now, the effectiveness of this device for
the treatment of CRHM has not been examined in a large-
scale study or in a multi-institutional trial. We have
recently published our initial pilot safety data demon-
strating this device to be safe in the treatment of metastatic
colorectal cancer[14].
The goals of this analysis was to: 1) gain a better under-
standing of the value of drug eluting bead therapy when
administered to patients with unresectable vascular
tumors of the liver. 2) Assess the limitations, concerns,
and complications that earlier users of drug eluting bead
therapy have encountered. This is our interim report of
those cases with unresectable liver metastases from color-
ectal cancer that have been treated with the Irinotecan
drug eluting bead (DEBIRI).
Methods
From January 2007 to October 2008, we conducted a pro-
spective, multi-institutional registry of 55 patients with
liver dominant metastatic colon cancer (MCC). Table 1
shows the participating sites in the US, Canada, Europe
and Australia. This registry was non-controlled, but it
received an IRB approval and complied with the protocol
and principles laid down in the Declaration of Helsinki,
in accordance with the ICH Harmonized Tripartite Guide-
line for Good Clinical Practice (GCP). The following crite-
ria were strictly observed: 1) The patient population was
well described; 2) The data were carefully obtained; 3)
Outcomes were independently assessed; 4) Follow up
information was clinically relevant, and few patients were
lost to follow up; 5) Comparable patient information was
obtained at all the participating institutions[15].
Each potential subject was given ample time to decide
whether to participate in the study and was informed that
they could withdraw at any time.
Inclusion criteria for chemoembolization were: 1) A con-
firmed diagnosis of liver dominant metastatic colorectal
cancer (by either a liver biopsy on past history of colon
cancer); 2) An ECOG Performance Status Score of 0 to 2
or a Karnofsky's Performance score of 60 to 100%; 3) Age
18 years or older; 4) Patient able to comprehend the
nature of the study and provide informed consent in
accordance with institutional and national guidelines.
Exclusion criteria were: 1) History of severe allergy or
intolerance to any contrast media not controlled with pre-
medication; 2) Bleeding diathesis, not correctable by the
usual forms of therapy; 3) Severe peripheral vascular dis-
ease that would preclude catheterization; 4) Significant
extra-hepatic disease, generally in excess of 50% of the
overall whole body tumor bulk outside the liver, or any
tumor burden that represented an imminent threat to the
patient's life; 5) Greater than 75% hepatic parenchymal
involvement; 6) Severe liver dysfunction; 6) An active,
uncontrolled infection.
Treatment was performed in an outpatient setting via a
lobar approach, based on the extent and distribution of
the disease. The method of DC/LC Bead therapy has been
described previously[14].
The drug eluting bead (DEBIRI) utilized in this report is
the DC/LC Bead™ (Biocompatibles, Farnham, UK), which
is a PVA microsphere with FDA clearance as a Class II
device. It is also CE marked as a Drug Delivery Emboliza-World Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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tion System. In this study, the DC/LC Bead was loaded
with irinotecan in an off label use. DC/LC Bead is availa-
ble in the size ranges of 100 - 300 μm, 300 - 500 μm, 500
- 700 μm and 700 - 900 μm. When loaded with irinotecan,
it can decrease in size by up to 30%. The dose is 50 mg/
ml, for a total dose of 100 mg per vial. The size of bead uti-
lized in each treatment was at the treating physicians dis-
cretion.
Irinotecan loaded DEBIRI is delivered by trans-arterial
chemoembolization (TACE). The primary function of the
device is to embolize the arteries feeding the tumor site,
causing tumor necrosis by starving it of nutrients and oxy-
gen. The secondary function is to deliver irinotecan in a
controlled manner. These functions combine to enhance
the toxic effect of the drug on the tumor while minimizing
systemic side effects.
All adverse events (AE) and serious adverse events (SAE)
were recorded using the standards and terminology set
forth by the Cancer Therapy Evaluation Program Com-
mon Terminology Criteria for Adverse Events, Version 3.0.
Adverse events, defined as an untoward deviation in
health away from baseline due to any cause, were
recorded during the hospital stay and for 30 days follow-
ing each treatment.
Follow-up assessments included a tri-phase CT scan of the
liver within at least one to two months from the treat-
ment. Evaluation of the enhancement pattern of the target
lesion and tumor response rates were measured according
to RECIST[16], EASL[17], and modified RECIST[18] crite-
ria.
Data entry was monitored for completeness and accuracy
at University of Louisville, and the data were queried
when indicated. Source documents were requested and
monitored for at least the first 5 patients from each site. A
central assessment of tumor response was performed for
all patients by the Principal Investigator at University of
Louisville. When there was a discrepancy, the Registry PI
and the site PI reexamined the data.
Once all the data were entered and all queries on data clar-
ification forms resolved, the database was locked and the
interim analysis performed. Data analysis was limited to
descriptive reports of the number and characteristics of
the patients treated and their clinical responses as well as
their adverse events. Descriptive statistics were used to
evaluate feasibility and safety. All demographic data have
been incorporated into a summary that includes age, race,
sex, height, weight, extent of liver disease, extent of
hepatic failure, and CEA level. Descriptive statistics
include the number and proportion of patients who com-
pleted planned therapy, the extent of hepatic and systemic
toxicity, and, if the data allowed, the response to therapy.
All subjects have been evaluated for safety. Exposure to
the study drug is summarized for all subjects. Summary
statistics also include adverse events, hematology (white
Table 1: Number of patients enrolled at each site.
Site Country Number of patients enrolled
University of Louisville US 21
Baptist Health, Little Rock, AR US 11
Colorado Springs US 3
Huntsville, AL US 10
Midland Memorial Hospital, TX US 1
Centar Nis Serbia Serbia 2
Usti Nad Labem Czech Republic 1
Regional Hospital Novy Jicin Czech Rebublic 1
FN v Motole Czech Republic 2
FH Plzen Czech Republic 1
Regional Oncological Dispenser, Samara Russia 2World Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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blood count, hemoglobin, and platelet count), and clini-
cal chemistry (ALT, AST, total bilirubin, prothrombin
time, and alkaline phosphatase). All toxicities were care-
fully monitored. Clinicopathologic data along with peri-
operative complications were recorded. Analysis of data
was done using JMP 4.0 and SPSS version 16.0.
Results
Fifty-five patients with CRHM underwent 99 total treat-
ments at the sites shown in Table 1. Forty were Caucasian,
9 African American, and 6 other. The median age of the
patients was 62 years and the range was 34 to 82 years old,
with more male (n = 34) than female (n = 21) (Table 2).
Twenty-eight patients had previously been treated with
hepatic surgery, 54 with prior systemic chemotherapy,
including FOLFOX in 35 patients, FOLFIRI in 15, Avastin
in 37 patients, and other biologics in 9, with 2 patients
receiving hepatic directed radiotherapy. The extent of liver
involvement was 57% were <25%, 34% 26-50%, 9% were
51-75% Liver replacement.
Fifty-five total patients under went 99 irinotecan bead
treatments, with most patients receiving 1 or 2 treatments
based on the extent and location of the liver disease (table
3). If patients had unilobar disease then most underwent
one treatment, if bilobar then two treatments. The extent
of hepatic tumor burden was most commonly multifocal
and involved the right lobe (Table 4). Extrahepatic disease
was present in 25 patients, with the most common loca-
tions being lung (n = 15), bone (n = 2), lymph nodes (n
= 5), and pelvis (n = 3). Median CEA levels at baseline
prior to treatment was 26, (range 1.9 to 3533). Karnofsky
status at baseline was prior to treatment 100-90 for most
patients.
In 50% of patients, treatment was performed over two or
more sessions (for example, where bilobar hepatic disease
was treated). The level of embolization was lobar in 80%
of treatments and segmental or subsegmental in 20%. A
total dose of 100 mg of irinotecan was generally loaded
into one DC/LC Bead vial (in most cases 100-300 microns
size) (Table 4). In the majority of cases (n = 90), 100% of
the loaded dose was administered for the first treatment
and 80% of the dose for subsequent treatments. Complete
occlusion was achieved in 28% of cases, near in 32%, and
partial occlusion was achieved in 40%. The most common
peri-procedural medications included opioids (100%),
antiemetics (100%), steroids (44%), antihypertensive
(82%), and intra-arterial lidocaine injection 2-4 cc prior
to DC/LC Bead injection (55%). Antibiotic prophylaxis
was at the physician's discretion and was used in 72% of
patients.
A total of 14 Adverse Events were reported in 55 patients
after the first treatment (Table 5). A statistically significant
difference in the incidence of any adverse event was seen
in patients who received greater that 100 mg versus
patients who received 100 mg or less as their first treat-
ment (p < 0.0001) The incidence of any adverse event dur-
ing the first treatment was greater in those patients who
received 100 mg or less than in those who received less
than 100 mg (p < 0.0001) (Table 6). A total of 16 patients
(29%) experienced 30 adverse events during the study
period (Table 7). During the treatment cycles, no changes
were seen in the liver chemistries or haematology param-
Table 2: Demographics based on treatment.
Variable Total
Gender Male 34
Female 21
Race Caucasian 40
African-American 9
Other 6
Age (years) N = 55
Mean 62
Median 62
± SD 10.6
Range 34-82
Weight (kg) N = 55
Mean 80.2
Median 79.5
± SD 17.6
Range 45.4-127.7
Height (cm) N = 55
Mean ± 148.5
Median 147.4
SD 9.3
Range 132-173.8
Body Surface (m2)N  =  5 5
Mean ± 1.928
Median 1.889
SD 0.25
Range 1.424-2.635World Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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eters. The median hospital stay was 23 hours (range 23
hour to 13 days).
During a median follow-up of 18 months, 12 patients
died, with the most common cause being disease progres-
sion (Table 8). Only one patient died of an SAE that was
judged to be an SAE possibly related to treatment. This 52
year-old male had a pre-operative bilirubin of 1.9 and an
INR of 2.0. His liver disease included 4 lesions in seg-
ments 5-8, with the largest lesion measuring 4.2 cm and a
total liver involvement of 26-50%. The total target lesion
size measured 12.9 cm. He also had extrahepatic disease
involving the pancreas, spleen, and lung. Treatment was
delivered to the right lobe and consisted of 2 vials of
DEBIRI loaded with 200 mg of Irinotecan. One vial con-
tained beads measuring 300-500 μm and the other con-
tained beads measuring 300-500 μm. Zofran was given
during the procedure, ciprofloxacin and flaygl were given
afterward, and pain was managed with an epidural. Fol-
lowing the procedure, the patient had a 3-day hospital
stay for nausea and was discharged home without inci-
dent. When the patient returned complaining of nausea
28 days after the procedure, he was diagnosed with liver
dysfunction, and died of this disorder 30 days later.
Table 3: MCC number of target lesions, size and location by CT.
Dose Administered 0-50 mg/m2 51-99 mg/m2 100 mg/m2 150 mg/m2 200 mg/m2 Total
Number of target lesions One 3 6 9 0 1 19
One + Satellites 2 1 0 0 1 4
T w o 2 1 9221 6
Multinodular 6 10 18 2 8 44
Mean number of target lesions N = 0 (missing)
N = 83
13 18 36 4 12 83
Mean ± Std 2.692 2.722 3.02 3 3.25 -
Median 2 3 2.5 2.5 3 -
Range 1-5 1-5 1-5 2-5 1-5 -
Anatomic site RHL 7 14 18 2 5 46
LHL 7 6 12 1 0 26
B o t h 0 1 3161 1
Diameter per tumour (cm) N (tumors) 35 48 109 12 39 243
Mean ± Std 2.58 2.59 3.17 4.125 3.9 -
Median 1.8 2 2.4 2.15 3.4 -
Range 1-10.1 0.5-7.4 1-14 1.1-9.5 1.5-12.2 -
Sum of diameter (cm) N = 0 (missing)
N = 83
13 18 36 4 12 83
Mean ± Std 6.95 7.02 9-575 12.375 12.63 -
Median 6.5 6.6 9.4 14.25 13.95 -
Range 3.6-10.3 1-18.1 2-20 3.5-17.5 1.6-19.7 -World Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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When treatment response was measured by the EASL cri-
teria, we had an observed response (defined as CR, PR,
and SD) in 89% of patients at 3 months, 80% at 6
months, and 54% at 12 months (Table 9). When treat-
ment response was judged by the RECIST criteria, 71%
responded at 3 months, 56% at 6 months, and 40% at 12
months, while 9 patients suffered progression in their
liver disease during follow up (Table 10). When the end-
point was any progression, either in the liver or elsewhere
in the body, the mean disease-free survival time was
206.09 days and the median disease-free survival time was
197 days (Figure 1). The median overall survival from the
time of first treatment was 247 days and the median was
343 days (Figure 1). Six patients (10%) were downstaged
from their original disease status. Of these, four were
treated with surgery and two with RFA.
Table 4: Details of Irinotecan DC/LC Bead Treatment.
Variable patients N
N of treatments = 99
Total # of patients = 55
One treatment 55(100%)
Two treatments 28 (50%)
Three treatments 12(9%)
≥Four treatments 4(5%)
Maximum number of treatment sessions (for patients with bilobar disease)
N (# of pts w/bilobar disease) 18
One session 2(11.1%)
Two sessions 11(61.1%)
Three, etc sessions 5(27.8%)
Irinotecan dose loaded per treatment Mean = 110.17
median = 100
SD +/- 45
Range = 50-200
Percentage of loaded volume per treatment ≤ 24 percent 2(2%)
25-49 1(1%)
50-74 13(13%)
≥ 75 83(84%)
Irinotecan dose administered per treatment 0-50 mg 15(15%)
51-99 mg 18(20%)
100 mg 50(50%)
150 mg 4(4%)
200 mg 12(12%)
Degree of occlusion achieved per treatment Complete 24(24%)
Partial 40(40%)
Near 35(35%)World Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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Predictors of overall survival from the time of first bead
treatment were evaluated in an attempt to identify factors
that predicted outcome. Neither number of liver lesions,
size of liver lesions or extent of liver replacement (<= 25%
vs >25%) were predictors of overall survival. Only the
presence of extrahepatic disease (p = 0,001), extent of
prior chemotherapy (failed 1st and 2nd liver vs > 2 line fail-
ure) (p = 0,007) were predictors of overall survival in mul-
tivariate analysis.
Discussion
This interim report includes data from five US based sites
and six European sites. All patients had unresectable
hepatic metastases from colorectal cancer and were
treated with at least one injection of Irinotecan-loaded
DEBIRI at dosages that ranged from 50 mg to 200 mg per
treatment.
When chemoembolization was first used to treat meta-
static colorectal cancer, the agent was a mixture of ethyl-
cellulose microcapsules and mitomycin C supplemented
with gelatin sponge[11]. Since then, a range of emboliza-
tion devices and ancillary drug regimens have been
employed [19-23]. The patient populations have varied
among the published studies, and because of this, caution
should be used when evaluating the results. In a recent
review, Vogl et al. report median survivals that range from
9 to 62 months and morphological responses that vary
from 14 to 76%[24].
In one of the largest series reported to date, Vogel et al
evaluated the efficacy of TACE for improving survival and
achieving local control in patients with liver metastases
from colorectal cancer[24]. Two hundred and seven
patients with liver metastases from colorectal cancer were
Table 5: Events after 1st treatment (based on dose received)
AE # Occurrences Event Rate %
50 mg dose
N = 3
Nausea 1 33.3
Vomiting 1 33.3
Hypertension 1 33.3
Liver Dysfunction 1 33.3
100 mg dose
N = 45
Nausea 2 4.4
Vomiting 1 2.2
Gastritis 1 2.2
Pain 1 2.2
Liver Dysfunction 1 2.2
150 mg dose
N = 1
Nausea 1 100
Vomiting 1 100
Anorexia 1 100
200 mg dose
N = 6
Liver dysfunction 1 16.7World Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
Page 8 of 12
(page number not for citation purposes)
Table 6: Incidence of Adverse Events by total dose administered (regardless of the interval of dosing).
AE
N = 30
<=100 mg dose Event Rate % <=200 Event Rate % <=300 Event Rate %
Nausea 2 6.7 3 10
V o m i t i n g 26 . 7 31 0
HTN 1 3 3 10
Infection 13
L i v e r  D y s f u n c t i o n 1 3 26 . 7 31 0
Gastritis 1 3
Dehydration 1 3
Cholecystitis 13
Anemia 1 3
Pneumonia 1 3
A n o r e x i a 2 6 13 13
Table 7: The type and incidence of adverse events by relation to bead treatment
Adverse Event 
Description
# events Adverse Event Grade Adverse Event 
Outcome
Adverse Event 
Relationship
Adverse Event 
Explain
Anorexia
(n = 3 patients)
3 Grade 2 Resolved Possibly Related PE syndrome
1 Grade 3 Resolved Possible Related
Hypertension
(N = 1 patient)
4 1-2 Resolved Not Related Pre-existing condition
Liver dysfunction/failure
(n = 4 patients)
3 1-2 Resolved Possibly Related Extent of Liver disease
2 3 Ongoing Possibly Related
1 5 Resolved Possibly Related
Nausea
(n = 4 patients)
5 1-2 Resolved Possibly Related PE syndrome
Vomiting
(n = 3 patients)
5 1-2 Resolved Possibly Related PE syndrome
Other: Gastritis, 
Dehydration, Anemia, 
Pneumonia
(n = 4 patients)
Cholecystitis
(n = 1 patient)
5 1-2 Resolved Possible Related Chemotherapy
1 3 Resolved Possibly Related Aberrant InfusionWorld Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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treated with repeated TACE in at 4-week intervals. A total
of 1,307 chemoembolizations were performed, with a
mean of 6.3 sessions per patient. The average age of the
207 patients was 68.8 years (range, 39.4-83.5 years). Of
these, 158 were treated for palliation, 35 to reduce symp-
toms, and 14 as adjuvant therapy. The chemotherapy con-
sisted of mitomycin C with or without gemcitabine, and
embolization was performed with lipiodol and starch
microspheres to achieve vessel occlusion. Local control
measured by the RECIST criteria were as follows: partial
response in 12% of patients, stable disease in 51% and
progressive disease in 37%. The 1-year survival rate after
TACE was 62%, but the 2-year survival rate was reduced to
38%. The median survival time from the date of diagnosis
of metastases was 3.4 years the median survival time from
the start of TACE treatment was 1.34 years. The median
survival time of the palliative group was 1.4 years, of the
symptomatic group 0.8 years and of the neoadjuvant
group 1.5 years. Vogl et al, concluded that TACE is an
effective minimally-invasive therapy for neoadjuvant,
symptomatic or palliative treatment of liver metastases in
colorectal cancer patients[24]. The results presented here
are comparable to Vogl's and they were achieved with sig-
nificantly fewer treatments (two versus six).
In spite of these promising results from a number of stud-
ies, none have demonstrated a significant improvement in
survival after chemoembolization[22]. observation, plus
the need for a more careful cost-benefit analysis, suggests
that additional prospective randomized trials should be
done [25-27]. The fact that substantial extrahepatic pro-
gression is often observed after regional treatment for liver
metastases further suggests that systemic chemotherapy
should be added to chemoembolization[28,29].
In this study, all the patients did not receive the same
adjunct medication or the same type of treatments with
the Irinotecan drug eluting device. Thus our data cannot
Table 8: Disposition of patients as per follow-up.
Screened 3 month 6 month 12 months 18 month
55 55 53 46 26
Reason for Death n (% from total n)
Disease Progression 12 (22)
SAE 1 (2)
a) Disease Free Survival of patients treated with Irinotecan drug eluting beads with liver dominant hepatic metastasis after fail- ing standard chemotherapy b) Overall Survival of patients treated with Irinotecan drug eluting beads with liver dominant  hepatic metastasis after failing standard chemotherapy Figure 1
a) Disease Free Survival of patients treated with Irinotecan drug eluting beads with liver dominant hepatic 
metastasis after failing standard chemotherapy b) Overall Survival of patients treated with Irinotecan drug 
eluting beads with liver dominant hepatic metastasis after failing standard chemotherapyWorld Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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be used to establish specific medical protocols for the US
or Europe.
The same number of patients received one treatment ver-
sus multiple treatments, while the vast majority of
patients received the planned pre-treatment loaded dose
based on vascularity as well as tumor distribution. There
was a 100% technical success in the use of the device, and
there were no significant serious adverse events related to
its insertion.
The safety of this device is shown by the fact that only one
patient suffered a serious adverse event. This patient had
an especially large tumor burden, which required a high
dose of irinotecan (200 mg). The remaining adverse event
profile is consistent with other well established as well as
historical hepatic arterial therapy treatments.
We observed a post-embolic syndrome (characterized by
nausea, vomiting, dehydration and pain) in patients who
received multiple treatments, with a cumulative dose of
300 mg or greater. However, none of these patients suf-
fered any serious adverse events associated with the treat-
ment. The clinical and laboratory evaluation showed no
significant variations in lab values that could be attributed
to treatment.
Table 9: EASL Tumour response.
Tumour Response (N = 55) 3 month 6 month 12 months 18 month
Complete Response 3 3 2 1
Partial Response 18 16 17 16
Stable Disease 28 25 11 8
Progressive Disease 5 2 4 1
Deaths 1 7 13 NA*
Not Reached Follow 0 2 7 29
Lost to Follow Up 0 0 2 0
Total 55 55 55 55
*Data not available at time of report but including at least 13 deaths
Table 10: RECIST Tumour response.
Tumour Response (N = 55) 3 month 6 month 12 months 18 month
Complete Response 2 2 1 1
Partial Response 4 2 2 2
Stable Disease 33 27 19 22
Progressive Disease 15 15 12 1
Deaths 1 7 13 NA*
Not Reached Follow 0 2 7 29
Lost to Follow Up 0 0 2 0
Total 55 55 55 55
*Data not available at time of report but including at least 13 deathsWorld Journal of Surgical Oncology 2009, 7:80 http://www.wjso.com/content/7/1/80
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Overall, we observed a very strong response rate at three
months and a durable response at both six and twelve
months in those patients that were measurable by EASL
criteria. Not surprisingly, the response rates were reduced
when measured by the traditional RECIST criteria,
because of its well-documented limitations[30].
The results of this study, when measured by time-to-pro-
gression and overall survival, represent a remarkable
achievement, given that most of the patients had already
been treated for their metastatic disease, some with as
many as three or four agents.
Conclusion
In conclusion, this interim report demonstrates that the
Irinotecan loaded DEBIRI is safe and effective in patients
with unresectable metastatic colorectal cancer. This treat-
ment shows a significant benefit for patients who have
failed first and second line therapy and is potentially an
effective therapy when compared to the historical
response rates to third and fourth line systemic chemo-
therapy.
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